SynthesisBMC neurology2025
Sleep disorders in Parkinson's disease: evaluating pharmacological treatments through systematic review and meta-analysis.
Synthesis in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacological treatment of sleep disorder phenotypes in Parkinson's disease: a systematic review and meta-analysis of randomised controlled trials.Journal of neurology · 2026Pooled it
- Correction: Sleep disorders in parkinson's disease: evaluating pharmacological treatments through systematic review and meta-analysis.BMC neurology · 2026Article
- Parkinson's disease beyond motor symptoms: a review of the validity and limitations of current classification of non-motor symptoms.Frontiers in psychiatry · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
Sleep disorders are the most common non-motor symptoms in patients with Parkinson’s disease (PD) and can significantly impact quality of life. However, the pharmacological treatments for sleep disorders in patients with PD remain controversial. Databases (PubMed, Embase, Web of Science, and the Cochrane Library) were searched up to 20 January 2025. Randomized controlled trials were included if they investigated the efficacy of pharmacological interventions for sleep disorders in populations with PD. The weighted mean difference (WMD) and standardized mean difference (SMD) were used as effect size. The random-effects model was applied due to the heterogeneity between studies. The certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation tool. A total of 23 studies were included in the systematic review and meta-analysis. Seven trials focused on the treatment of rapid eye movement sleep behavior disorder (RBD), seven on excessive daytime sleepiness (EDS), six on insomnia, and three on sleep disorders that were not specifically classified. The meta-analysis showed that pharmacological interventions were effective in improving EDS (SMD: -0.36; 95% CI: -0.63, -0.10) and insomnia in patients with PD (SMD: -0.53; 95% CI: -0.82, -0.24). However, pharmacological interventions did not show significant benefits for managing RBD (SMD: -0.19; 95% CI: -0.54, 0.16). The certainty of evidence across all studies ranged from very low to moderate. In population with PD, pharmacological interventions were effective in improving EDS and insomnia. However, the management of RBD with pharmacological treatments remains challenging. In the future, strong evidence is needed to address this challenge.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.